{
  "name": "Metastatic Breast Cancer",
  "states": {

    "Initial": {
      "type": "Initial",
      "conditional_transition": [
        {
          "condition": {
            "condition_type": "Gender",
            "gender": "F"
          },
          "transition": "Select_For_Metastatic_Breast_Cancer"
        },
        {
          "transition": "Terminal"
        }
      ]
    },

    "Select_For_Metastatic_Breast_Cancer": {
      "type": "Simple",
      "remarks": [
        "1/8 women get breast cancer, 20-25% of those are stage IV at diagnosis.",
        "(1 / 8) * 0.25 => 0.03125 probability of getting stage IV breast cancer."
      ],
      "distributed_transition": [
        {
          "distribution": 0.03125,
          "transition": "Delay_For_Adulthood"
        },
        {
          "distribution": 0.96875,
          "transition": "Terminal"
        }
      ]
    },

    "Delay_For_Adulthood": {
      "type": "Delay",
      "remarks": [
        "On average women start getting annual mammograms at age 40. Not all women in ",
        "this pool will necessarily elect to get mammograms."
      ],
      "range": {
        "low": 35,
        "high": 45,
        "unit": "years"
      },
      "distributed_transition": [
        {
          "distribution": 0.8,
          "transition": "Ellective_Annual_Mammogram"
        },
        {
          "distribution": 0.2,
          "transition": "No_Ellective_Annual_Mammogram"
        }
      ]
    },

    "No_Ellective_Annual_Mammogram": {
      "type": "Simple",
      "direct_transition": "Delay_Until_Symptoms_Present"
    },

    "Delay_Until_Symptoms_Present": {
      "type": "Delay",
      "remarks": [
        "Of those women who do not get an annual mammogram, their breast cancer ",
        "will not be diagnosed until they present with symptoms and seek medical ",
        "attention."
      ],
      "range": {
        "low": 0,
        "high": 20,
        "unit": "years"
      },
      "direct_transition": "Symptoms_Present"
    },

    "Symptoms_Present": {
      "type": "Simple",
      "remarks": [
        "At this point in the module these women are experiencing symptoms bad enough ",
        "to merit a visit to the doctor."
      ],
      "direct_transition": "Encounter_For_Symptoms"
    },

    "Ellective_Annual_Mammogram": {
      "type": "CallSubmodule",
      "submodule": "procedures/metastatic_breast_cancer/mammogram",
      "direct_transition": "Abormal_Finding?"
    },

    "Abormal_Finding?": {
      "type": "Simple",
      "remarks": [
        "Following the annual mammogram, 2% of women will show abnormalities due to ",
        "breast cancer. The remainder will go back into the candidate pool and wait ",
        "until next year's mammogram."
      ],
      "distributed_transition": [
        {
          "distribution": 0.02,
          "transition": "Abnormality_Detected"
        },
        {
          "distribution": 0.98,
          "transition": "No_Abnormality_Detected"
        }
      ]
    },

    "Abnormality_Detected": {
      "type": "Simple",
      "direct_transition": "Delay_For_Mammogram_Review"
    },

    "No_Abnormality_Detected": {
      "type": "Simple",
      "direct_transition": "Delay_For_Next_Mammogram"
    },

    "Delay_For_Next_Mammogram": {
      "type": "Delay",
      "remarks": [
        "All women in the candidate pool will present with stage IV breast cancer ",
        "by age 65, many sooner than that."
      ],
      "range": {
        "low": 11,
        "high": 14,
        "unit": "months"
      },
      "conditional_transition": [
        {
          "condition": {
            "condition_type": "Age",
            "operator": ">=",
            "quantity": 65,
            "unit": "years"
          },
          "transition": "Symptoms_Present"
        },
        {
          "transition": "Ellective_Annual_Mammogram"
        }
      ]
    },

    "Encounter_For_Symptoms": {
      "type": "Encounter",
      "remarks": [
        "These women have not had a mammogram before. Once symptoms present these ",
        "women seek medical care."
      ],
      "encounter_class": "ambulatory",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": "185345009",
          "display": "Encounter for symptom"
        }
      ],
      "direct_transition": "Physical_Examination"
    },

    "Physical_Examination": {
      "type": "Procedure",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": "5880005",
          "display": "Physical examination"
        }
      ],
      "direct_transition": "End_Encounter_For_Symptoms"
    },

    "End_Encounter_For_Symptoms": {
      "type": "EncounterEnd",
      "direct_transition": "Delay_For_Initial_Diagnostic_Mammogram"
    },

    "Delay_For_Initial_Diagnostic_Mammogram": {
      "type": "Delay",
      "range": {
        "low": 1,
        "high": 3,
        "unit": "days"
      },
      "direct_transition": "Initial_Diagnostic_Mammogram"
    },

    "Initial_Diagnostic_Mammogram": {
      "type": "CallSubmodule",
      "submodule": "procedures/metastatic_breast_cancer/mammogram",
      "direct_transition": "Delay_For_Mammogram_Review"
    },

    "Delay_For_Mammogram_Review": {
      "type": "Delay",
      "range": {
        "low": 1,
        "high": 3,
        "unit": "days"
      },
      "direct_transition": "Diagnosis_Encounter_Post_Mammogram"
    },

    "Diagnosis_Encounter_Post_Mammogram": {
      "type": "Encounter",
      "remarks": [
        "Once breast cancer is suspected (and at least one recent mammogram has been ",
        "performed to confirm), all women will have a followup encounter to review ",
        "the mammogram findings and to perform an initial biopsy and suite of tests."
      ],
      "encounter_class": "ambulatory",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": "185345009",
          "display": "Encounter for symptom"
        }
      ],
      "direct_transition": "Mammogram_Findings"
    },

    "Mammogram_Findings": {
      "type": "Simple",
      "remarks": [
        "TODO: Make observations about the results of the mammogram."
      ],
      "direct_transition": "Breast_Biopsy"
    },

    "Breast_Biopsy": {
      "type": "Procedure",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": "122548005",
          "display": "Biopsy of breast"
        }
      ],
      "direct_transition": "Biopsy_Findings"
    },

    "Biopsy_Findings": {
      "type": "Simple",
      "remarks": [
        "TODO: Make observations about the results of the biopsy."
      ],
      "direct_transition": "ImmunoHistoChemistry_Test"
    },

    "ImmunoHistoChemistry_Test": {
      "type": "Procedure",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": "117617002",
          "display": "Immunohistochemistry procedure"
        }
      ],
      "direct_transition": "ImmunoHistoChemistry_Test_Findings"
    },

    "ImmunoHistoChemistry_Test_Findings": {
      "type": "Simple",
      "remarks": [
        "TODO: Record the results of the IHC test."
      ],
      "direct_transition": "Stage_IV_Breast_Cancer"
    },

    "Stage_IV_Breast_Cancer": {
      "type": "ConditionOnset",
      "target_encounter": "Diagnosis_Encounter_Post_Mammogram",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": "254837009",
          "display": "Malignant neoplasm of breast"
        }
      ],
      "direct_transition": "End_Diagnosis_Encounter"
    },

    "End_Diagnosis_Encounter": {
      "type": "EncounterEnd",
      "direct_transition": "Receptor_Status"
    },

    "Receptor_Status": {
      "type": "Simple",
      "remarks": [
        "70% HR+/HER2-; 15% HR-/HER2+; 15% HR-/HER2- "
      ],
      "distributed_transition": [
        {
          "distribution": 0.7,
          "transition": "HR+/HER2-"
        },
        {
          "distribution": 0.15,
          "transition": "HR-/HER2+"
        },
        {
          "distribution": 0.15,
          "transition": "HR-/HER2-"
        }
      ]
    },

    "HR+/HER2-": {
      "type": "Simple",
      "remarks": [
        "======================================================================",
        "HR+/HER2- Endocrine Therapy                                           ",
        "======================================================================"
      ],
      "direct_transition": "HR+/HER2-_Endocrine_Therapy_Initial_Encounter"
    },

    "HR+/HER2-_Endocrine_Therapy_Initial_Encounter": {
      "type": "Encounter",
      "remarks": [
        "This is the initial encounter to begin endocrine therapy. ",
        "The patient is prescribed either Anastrazole or Tamoxifen ",
        "depending on her age, then started on the treatment cycle."
      ],
      "encounter_class": "ambulatory",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": "308335008",
          "display": "Patient encounter procedure"
        }
      ],
      "conditional_transition": [
        {
          "condition": {
            "condition_type": "Age",
            "operator": ">=",
            "quantity": 50,
            "unit": "years"
          },
          "transition": "HR+/HER2-_Prescribe_Anastrazole"
        },
        {
          "transition": "HR+/HER2-_Prescribe_Tamoxifen"
        }
      ]
    },

    "HR+/HER2-_Prescribe_Anastrazole": {
      "type": "MedicationOrder",
      "reason": "Stage_IV_Breast_Cancer",
      "codes": [
        {
          "system": "RxNorm",
          "code": "199224",
          "display": "Anastrazole 1MG Oral Tablet"
        }
      ],
      "direct_transition": "HR+/HER2-_Baseline_Exam"
    },

    "HR+/HER2-_Prescribe_Tamoxifen": {
      "type": "MedicationOrder",
      "reason": "Stage_IV_Breast_Cancer",
      "codes": [
        {
          "system": "RxNorm",
          "code": "198240",
          "display": "Tamoxifen 10MG Oral Tablet"
        }
      ],
      "direct_transition": "HR+/HER2-_Baseline_Exam"
    },

    "HR+/HER2-_Baseline_Exam": {
      "type": "CallSubmodule",
      "submodule": "procedures/metastatic_breast_cancer/full_exam",
      "direct_transition": "HR+/HER2-_End_Endocrine_Therapy_Initial_Encounter"
    },

    "HR+/HER2-_End_Endocrine_Therapy_Initial_Encounter": {
      "type": "EncounterEnd",
      "direct_transition": "HR+/HER2-_Endocrine_Therapy_Cycle"
    },

    "HR+/HER2-_Endocrine_Therapy_Cycle": {
      "type": "Delay",
      "exact": {
        "quantity": 8,
        "unit": "weeks"
      },
      "direct_transition": "HR+/HER2-_Endocrine_Therapy_Check_Up"
    },

    "HR+/HER2-_Endocrine_Therapy_Check_Up": {
      "type": "Encounter",
      "encounter_class": "ambulatory",
      "direct_transition": "HR+/HER2-_Routine_Exam"
    },

    "HR+/HER2-_Routine_Exam": {
      "type": "CallSubmodule",
      "submodule": "procedures/metastatic_breast_cancer/full_exam",
      "direct_transition": "HR+/HER2-_End_Endocrine_Therapy_Check_Up"
    },

    "HR+/HER2-_End_Endocrine_Therapy_Check_Up": {
      "type": "EncounterEnd",
      "direct_transition": "HR+/HER2-_Progression?"
    },

    "HR+/HER2-_Progression?": {
      "type": "Simple",
      "remarks": [
        "50% of patients have a 1st progression by 13 months. Given 8 weeks/cycle, ",
        "that's roughly 7 cycles before 50% of patients have progressed.",
        "Model: P(progression) = 0.93 ^ n_cycles "
      ],
      "distributed_transition": [
        {
          "distribution": 0.93,
          "transition": "HR+/HER2-_Endocrine_Therapy_Cycle"
        },
        {
          "distribution": 0.07,
          "transition": "HR+/HER2-_First_Progression"
        }
      ]
    },

    "HR+/HER2-_First_Progression": {
      "type": "Simple",
      "direct_transition": "HR+/HER2-_Living_With_Progressing_Metastatic_Breast_Cancer"
    },

    "HR+/HER2-_Living_With_Progressing_Metastatic_Breast_Cancer": {
      "type": "Simple",
      "direct_transition": "HR+/HER2-_Diminishing_Likelihood_Of_Survival"
    },

    "HR+/HER2-_Diminishing_Likelihood_Of_Survival": {
      "type": "Delay",
      "remarks": [
        "Annual chances of survival decay exponentially. 50% of patients die ",
        "within 50 months of their first progression.",
        "Model: P(survival) = .845 ^ n_years "
      ],
      "exact": {
        "quantity": 1,
        "unit": "years"
      },
      "distributed_transition": [
        {
          "distribution": 0.845,
          "transition": "HR+/HER2-_Living_With_Progressing_Metastatic_Breast_Cancer"
        },
        {
          "distribution": 0.155,
          "transition": "Death"
        }
      ]
    },

    "HR-/HER2+": {
      "type": "Simple",
      "remarks": [
        "======================================================================",
        "HR-/HER2+ Chemotherapy and Endocrine Therapy                          ",
        "======================================================================"
      ],
      "direct_transition": "HR-/HER2+_Therapy_Initial_Encounter"
    },

    "HR-/HER2+_Therapy_Initial_Encounter": {
      "type": "Encounter",
      "remarks": [
        "This is the initial encounter to begin 'combo' encodrine + chemo ",
        "therapy. For chemotherapy the patient is prescribed either Pertuzimab, ",
        "Trastuzimab, or Taxane. For endocrine therapy, the patient is prescribed ",
        "either Anastrazole or Tamoxifen depending on her age."
      ],
      "encounter_class": "ambulatory",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": "308335008",
          "display": "Patient encounter procedure"
        }
      ],
      "direct_transition": "HR-/HER2+_Select_Chemotherapy_Drug"
    },

    "HR-/HER2+_Select_Chemotherapy_Drug": {
      "type": "Simple",
      "distributed_transition": [
        {
          "distribution": 0.34,
          "transition": "HR-/HER2+_Prescribe_Pertuzimab"
        },
        {
          "distribution": 0.33,
          "transition": "HR-/HER2+_Prescribe_Trastuzimab"
        },
        {
          "distribution": 0.33,
          "transition": "HR-/HER2+_Prescribe_Taxane"
        }
      ]
    },

    "HR-/HER2+_Prescribe_Pertuzimab": {
      "type": "MedicationOrder",
      "codes": [
        {
          "system": "RxNorm",
          "code": "1298948",
          "display": "14 ML pertuzumab 30 MG/ML Injection"
        }
      ],
      "direct_transition": "HR-/HER2+_Select_Endocrine_Therapy_Drug"
    },

    "HR-/HER2+_Prescribe_Trastuzimab": {
      "type": "MedicationOrder",
      "codes": [
        {
          "system": "RxNorm",
          "code": "1922509",
          "display": "Trastuzumab 150 MG Injection"
        }
      ],
      "direct_transition": "HR-/HER2+_Select_Endocrine_Therapy_Drug"
    },

    "HR-/HER2+_Prescribe_Taxane": {
      "type": "MedicationOrder",
      "codes": [
        {
          "system": "RxNorm",
          "code": "583214",
          "display": "PACLitaxel 100 MG Injection"
        }
      ],
      "direct_transition": "HR-/HER2+_Select_Endocrine_Therapy_Drug"
    },

    "HR-/HER2+_Select_Endocrine_Therapy_Drug": {
      "type": "Simple",
      "conditional_transition": [
        {
          "condition": {
            "condition_type": "Age",
            "operator": ">=",
            "quantity": 50,
            "unit": "years"
          },
          "transition": "HR-/HER2+_Prescribe_Anastrazole"
        },
        {
          "transition": "HR-/HER2+_Prescribe_Tamoxifen"
        }
      ]
    },

    "HR-/HER2+_Prescribe_Anastrazole": {
      "type": "MedicationOrder",
      "reason": "Stage_IV_Breast_Cancer",
      "codes": [
        {
          "system": "RxNorm",
          "code": "199224",
          "display": "Anastrazole 1MG Oral Tablet"
        }
      ],
      "direct_transition": "HR-/HER2+_Baseline_Exam"
    },

    "HR-/HER2+_Prescribe_Tamoxifen": {
      "type": "MedicationOrder",
      "reason": "Stage_IV_Breast_Cancer",
      "codes": [
        {
          "system": "RxNorm",
          "code": "198240",
          "display": "Tamoxifen 10MG Oral Tablet"
        }
      ],
      "direct_transition": "HR-/HER2+_Baseline_Exam"
    },

    "HR-/HER2+_Baseline_Exam": {
      "type": "CallSubmodule",
      "submodule": "procedure/metastatic_breast_cancer/full_exam",
      "direct_transition": "HR-/HER2+_End_Therapy_Initial_Encounter"
    },

    "HR-/HER2+_End_Therapy_Initial_Encounter": {
      "type": "EncounterEnd",
      "direct_transition": "HR-/HER2+_Combo_Therapy_Cycle"
    },

    "HR-/HER2+_Combo_Therapy_Cycle": {
      "type": "Delay",
      "exact": {
        "quantity": 8,
        "unit": "weeks"
      },
      "direct_transition": "HR-/HER2+_Combo_Therapy_Check_Up"
    },

    "HR-/HER2+_Combo_Therapy_Check_Up": {
      "type": "Encounter",
      "encounter_class": "ambulatory",
      "direct_transition": "HR-/HER2+_Routine_Exam"
    },

    "HR-/HER2+_Routine_Exam": {
      "type": "CallSubmodule",
      "submodule": "procedures/metastatic_breast_cancer/full_exam",
      "direct_transition": "HR-/HER2+_End_Combo_Therapy_Check_Up"
    },

    "HR-/HER2+_End_Combo_Therapy_Check_Up": {
      "type": "EncounterEnd",
      "direct_transition": "HR-/HER2+_Progression?"
    },

    "HR-/HER2+_Progression?": {
      "type": "Simple",
      "remarks": [
        "50% of patients have a 1st progression by 9 months. Given 8 weeks/cycle, ",
        "that's roughly 5 cycles before 50% of patients have progressed.",
        "Model: P(progression) = 0.87 ^ n_cycles "
      ],
      "distributed_transition": [
        {
          "distribution": 0.87,
          "transition": "HR-/HER2+_Combo_Therapy_Cycle"
        },
        {
          "distribution": 0.13,
          "transition": "HR-/HER2+_First_Progression"
        }
      ]
    },

    "HR-/HER2+_First_Progression": {
      "type": "Simple",
      "direct_transition": "HR-/HER2+_Living_With_Progressing_Metastatic_Breast_Cancer"
    },

    "HR-/HER2+_Living_With_Progressing_Metastatic_Breast_Cancer": {
      "type": "Simple",
      "direct_transition": "HR-/HER2+_Diminishing_Likelihood_Of_Survival"
    },

    "HR-/HER2+_Diminishing_Likelihood_Of_Survival": {
      "type": "Delay",
      "remarks": [
        "Annual chances of survival decay exponentially. 50% of patients die ",
        "within 48 months of their first progression.",
        "Model: P(survival) = .84 ^ n_years "
      ],
      "exact": {
        "quantity": 1,
        "unit": "years"
      },
      "distributed_transition": [
        {
          "distribution": 0.84,
          "transition": "HR-/HER2+_Living_With_Progressing_Metastatic_Breast_Cancer"
        },
        {
          "distribution": 0.16,
          "transition": "Death"
        }
      ]
    },

    "HR-/HER2-": {
      "type": "Simple",
      "remarks": [
        "======================================================================",
        "HR-/HER2- Chemotherapy                                                ",
        "======================================================================"
      ],
      "direct_transition": "HR-/HER2-_Therapy_Initial_Encounter"
    },

    "HR-/HER2-_Therapy_Initial_Encounter": {
      "type": "Encounter",
      "remarks": [
        "This is the initial encounter to begin chemotherapy. The patient is ",
        "prescribed either Taxane or Capecitabine."
      ],
      "encounter_class": "ambulatory",
      "codes": [
        {
          "system": "SNOMED-CT",
          "code": "308335008",
          "display": "Patient encounter procedure"
        }
      ],
      "direct_transition": "HR-/HER2-_Select_Chemotherapy_Drug"
    },

    "HR-/HER2-_Select_Chemotherapy_Drug": {
      "type": "Simple",
      "distributed_transition": [
        {
          "distribution": 0.5,
          "transition": "HR-/HER2-_Prescribe_Taxane"
        },
        {
          "distribution": 0.5,
          "transition": "HR-/HER2-_Prescribe_Capecitabine"
        }
      ]
    },

    "HR-/HER2-_Prescribe_Taxane": {
      "type": "MedicationOrder",
      "codes": [
        {
          "system": "RxNorm",
          "code": "583214",
          "display": "PACLitaxel 100 MG Injection"
        }
      ],
      "direct_transition": "HR-/HER2-_Baseline_Exam"
    },

    "HR-/HER2-_Prescribe_Capecitabine": {
      "type": "MedicationOrder",
      "codes": [
        {
          "system": "RxNorm",
          "code": "200327",
          "display": "Capecitabine 150 MG Oral Tablet"
        }
      ],
      "direct_transition": "HR-/HER2-_Baseline_Exam"
    },

    "HR-/HER2-_Baseline_Exam": {
      "type": "CallSubmodule",
      "submodule": "procedures/metastatic_breast_cancer/full_exam",
      "direct_transition": "HR-/HER2-_End_Therapy_Initial_Encounter"
    },

    "HR-/HER2-_End_Therapy_Initial_Encounter": {
      "type": "EncounterEnd",
      "direct_transition": "HR-/HER2-_Chemotherapy_Cycle"
    },

    "HR-/HER2-_Chemotherapy_Cycle": {
      "type": "Delay",
      "exact": {
        "quantity": 8,
        "unit": "weeks"
      },
      "direct_transition": "HR-/HER2-_Chemotherapy_Check_Up"
    },

    "HR-/HER2-_Chemotherapy_Check_Up": {
      "type": "Encounter",
      "encounter_class": "ambulatory",
      "direct_transition": "HR-/HER2-_Routine_Exam"
    },

    "HR-/HER2-_Routine_Exam": {
      "type": "CallSubmodule",
      "submodule": "procedures/metastatic_breast_cancer/full_exam",
      "direct_transition": "HR-/HER2-_End_Chemotherapy_Check_Up"
    },

    "HR-/HER2-_End_Chemotherapy_Check_Up": {
      "type": "EncounterEnd",
      "direct_transition": "HR-/HER2-_Progression?"
    },

    "HR-/HER2-_Progression?": {
      "type": "Simple",
      "remarks": [
        "50% of patients have a 1st progression by 12 weeks. Given 8 weeks/cycle, ",
        "that's roughly 2 cycles before 50% of patients have progressed.",
        "Model: P(progression) = 0.7 ^ n_cycles "
      ],
      "distributed_transition": [
        {
          "distribution": 0.7,
          "transition": "HR-/HER2-_Chemotherapy_Cycle"
        },
        {
          "distribution": 0.3,
          "transition": "HR-/HER2-_First_Progression"
        }
      ]
    },

    "HR-/HER2-_First_Progression": {
      "type": "Simple",
      "direct_transition": "HR-/HER2-_Living_With_Progressing_Metastatic_Breast_Cancer"
    },

    "HR-/HER2-_Living_With_Progressing_Metastatic_Breast_Cancer": {
      "type": "Simple",
      "direct_transition": "HR-/HER2-_Diminishing_Likelihood_Of_Survival"
    },

    "HR-/HER2-_Diminishing_Likelihood_Of_Survival": {
      "type": "Delay",
      "remarks": [
        "Annual chances of survival decay exponentially. 50% of patients die ",
        "within 13 months of their first progression.",
        "Model: P(survival) = .51 ^ n_years "
      ],
      "exact": {
        "quantity": 1,
        "unit": "years"
      },
      "distributed_transition": [
        {
          "distribution": 0.51,
          "transition": "HR-/HER2-_Living_With_Progressing_Metastatic_Breast_Cancer"
        },
        {
          "distribution": 0.49,
          "transition": "Death"
        }
      ]
    },

    "Death": {
      "type": "Death",
      "direct_transition": "Terminal"
    },

    "Terminal": {
      "type": "Terminal"
    }
  }
}
